Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$87.98 USD
+0.52 (0.59%)
Updated May 24, 2024 04:00 PM ET
After-Market: $87.97 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$87.98 USD
+0.52 (0.59%)
Updated May 24, 2024 04:00 PM ET
After-Market: $87.97 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Zacks News
Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
Bruker's (BRKR) New Buyout to Advance Digital Transformation
by Zacks Equity Research
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.
Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
by Zacks Equity Research
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.
Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook
by Zacks Equity Research
Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips
by Zacks Equity Research
According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.
OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.
QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.
Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up
by Zacks Equity Research
Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.
Envista (NVST) Q1 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.
BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.
Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
Inari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all its growth drivers.
Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.
CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut
by Zacks Equity Research
CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.